Encompass Health Is Below Fair Value After a 110% Run-If Earnings Keep Up

Encompass Health after a 110% rally: premium setup, still needing proof

At roughly $11.2 billion market capitalization and 17.27x forward P/E, Encompass Health is no longer a hidden idea. Trading at $112.89 inside a $93.83 to $127.18 52-week range, it looks more like a premium setup near historical highs than a distressed bargain. After the recent 110% run, the question is not whether the story is compelling. It is whether today's price still allows for meaningful upside, or whether much of the next leg is already in the stock.

The valuation debate rests on execution

Bulls can point to supportive signals: 13 buy ratings and a stock still trading below the high end of published analyst targets. Bears will note that the shares are already close to the top of the 52-week range, and a 17.27x forward P/E leaves less room for a guidance hold, a slowdown, or a multiple reset. So the thesis now depends on execution. If Encompass keeps compounding earnings from a higher base, the current price can still be validated. If not, the easiest part of the move may already be behind it.

Why "below fair value" depends on earnings growth, not just the growth story

The "below fair value" label only holds if Encompass Health keeps raising the earnings base beneath the current multiple. One strong quarter does not make the stock cheap.

The latest quarter improved the valuation math

Q2 improved the setup in the right places. Revenue reached $1.60 billion, up 9.6% year over year. Adjusted EPS was $1.55, ahead of consensus, and adjusted EBITDA margin was 21.8%. Management also raised full-year revenue guidance to about $6.45 billion and adjusted EPS guidance to $6.14. That matters more than a one-quarter beat because it lifts the earnings base the market is already underwriting.

What has to stay intact for the thesis to hold

A premium multiple is easier to defend when growth comes from the established facility base, not only from new capacity. That is why the next few quarters matter: fair value moves with earnings, not just with optimism.

Where the bear case still has traction

The bear case does not require disputing the quarter. It only requires the next steps to wobble. If guidance stops rising, margin pressure returns, or beats become harder to sustain, the main support for the "still below fair value" argument weakens. At that point, execution risk stops being theoretical.

What could move EHC toward or away from fair value over the next few quarters

The next one to two earnings cycles matter less for reversing the stock's recent bounce than for testing whether Encompass can keep compounding from a higher operating base.

Operating leverage and capacity are the main upside drivers

The clearest bullish lever is operating leverage. In the latest quarter, Encompass produced 21.8% adjusted EBITDA margin and an 11.1% free cash flow margin. If EBITDA margin stays above 21% for a couple of quarters, earnings can grow faster than revenue and the valuation becomes easier to support.

Capacity expansion is the second lever. Management said it opened a new 49-bed hospital in Irmo, South Carolina. In the same quarter, discharges rose 4.3%, same-store discharge growth was 1.6%, and net patient revenue per discharge increased 3.7%. That suggests both volume and case mix are helping. But new beds create fair value only if they fill profitably.

The main risks are slowing same-store trends and weaker cash conversion

The counterargument is simpler. Same-store sales slowed to 2.8% from 4.7% a year earlier, and free cash flow margin fell from 12.8% to 11.1%. If same-store momentum cools further while margins slip below the low-20% range, fair value can move lower even if revenue still grows.

How to approach Encompass Health from here

The stock now needs confirmation, not another retelling of the growth story.

What would count as proof

• A follow-through quarter that repeats the last beat, including revenue above expectations, adjusted EPS ahead of consensus, and no obvious softening in the underlying operating trend.
• Another round of guidance upside that lets the market keep paying a premium.
• Price action that holds strength without needing a dramatic chase after an overextended move.

What to watch next

• Whether revenue beats reflect durable demand rather than timing.
• Whether cash conversion remains healthy after the recent free cash flow margin decline.
• Whether same-store trends stabilize instead of slipping again from the last reported pace.

What would weaken the setup

Step back if Encompass merely meets consensus, cuts guidance, or shows clear deterioration in same-store trends and margins. The practical rule is simple: add only on proof, not on the appeal of the story alone.